title: A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
abstract: Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4-50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0-75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5-41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5-31.2%) for ETTL to 56.5% (95% CI 42.8-69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.
authors.affiliation: Department of Internal Medicine, Mercer University, Central Georgia Cancer Care, 1062 Forsyth Street, Suite 1B Macon, Georgia, GA 31201, USA.
authors.forename: Abeer N
authors.initials: AN
authors.lastname: Abouyabis
authors.forename: Pareen J
authors.initials: PJ
authors.lastname: Shenoy
authors.forename: Rajni
authors.initials: R
authors.lastname: Sinha
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Lechowicz
references.citation: Blood. 2010 Nov 4;116(18):3418-25
references.pmid: 20660290
references.citation: Br J Radiol. 1982 Sep;55(657):645-9
references.pmid: 7127005
references.citation: Eur J Haematol. 2010 May;84(5):391-7
references.pmid: 20059527
references.citation: Cancer. 2004 Jan 15;100(2):366-75
references.pmid: 14716773
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Cancer Chemother Pharmacol. 2006 Jul;58(1):35-9
references.pmid: 16308699
references.citation: Cancer. 2004 Jan 15;100(2):342-9
references.pmid: 14716770
references.citation: Leuk Lymphoma. 2010 Mar;51(3):447-55
references.pmid: 20141439
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Br J Haematol. 2005 May;129(3):366-72
references.pmid: 15842660
references.citation: Ann Oncol. 2001 Mar;12(3):349-52
references.pmid: 11332147
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Blood. 2007 Oct 1;110(7):2316-23
references.pmid: 17581918
references.citation: Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90
references.pmid: 12182990
references.citation: Radiother Oncol. 2001 Dec;61(3):261-9
references.pmid: 11730995
references.citation: J Clin Oncol. 1999 Oct;17(10):3117-21
references.pmid: 10506607
references.citation: Blood. 2004 Jan 1;103(1):216-21
references.pmid: 12933580
references.citation: Ann Oncol. 2002 Jan;13(1):140-9
references.pmid: 11863096
references.citation: Ann Oncol. 2004 Apr;15(4):618-25
references.pmid: 15033670
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1426-7
references.pmid: 11870192
references.citation: Haematologica. 2007 Feb;92(2):271-2
references.pmid: 17296587
references.citation: Ann Oncol. 1990;1(1):45-50
references.pmid: 1706610
references.citation: Ann Oncol. 1998 Aug;9(8):849-55
references.pmid: 9789607
references.citation: Leukemia. 2001 Jul;15(7):1123-6
references.pmid: 11455983
references.citation: Leukemia. 2005 Dec;19(12):2186-94
references.pmid: 16179910
references.citation: Br J Haematol. 1997 Jun;97(4):821-9
references.pmid: 9217183
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1182-9
references.pmid: 21245435
references.citation: J Clin Oncol. 1998 Jan;16(1):70-7
references.pmid: 9440725
references.citation: Ai Zheng. 2004 Nov;23(11 Suppl):1443-7
references.pmid: 15566653
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: Cancer. 2005 May 15;103(10):2091-8
references.pmid: 15816054
references.citation: Blood. 2004 Aug 1;104(3):626-33
references.pmid: 14982884
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Blood. 2003 Dec 15;102(13):4284-9
references.pmid: 12920037
references.citation: Braz J Med Biol Res. 2006 Oct;39(10):1315-22
references.pmid: 16906323
references.citation: Br J Haematol. 2007 Jan;136(1):111-3
references.pmid: 17116129
references.citation: Biometrics. 2000 Jun;56(2):455-63
references.pmid: 10877304
references.citation: Ann Intern Med. 1992 Sep 1;117(5):364-70
references.pmid: 1380221
references.citation: Ann Oncol. 2004 Nov;15(11):1680-3
references.pmid: 15520071
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references.pmid: 18626005
references.citation: Blood. 2004 Aug 1;104(3):634-41
references.pmid: 15016643
references.citation: Jpn J Clin Oncol. 2005 Jan;35(1):1-5
references.pmid: 15681596
references.citation: Ann Oncol. 2004 Dec;15(12):1790-7
references.pmid: 15550584
references.citation: Hematol Oncol. 1992 May-Aug;10(3-4):155-61
references.pmid: 1383118
references.citation: Am J Hematol. 2001 Jul;67(3):172-8
references.pmid: 11391714
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4117-26
references.pmid: 15867204
references.citation: Br J Haematol. 2006 Jul;134(1):45-53
references.pmid: 16803566
references.citation: J Clin Oncol. 2009 Jan 1;27(1):106-13
references.pmid: 19029417
references.citation: Leuk Lymphoma. 1999 Feb;32(5-6):545-52
references.pmid: 10048427
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:280-8
references.pmid: 19074097
references.citation: J Pathol. 1997 Sep;183(1):44-50
references.pmid: 9370946
references.citation: J Clin Oncol. 1989 Aug;7(8):1018-26
references.pmid: 2474057
references.citation: Blood. 2003 Sep 1;102(5):1842-8
references.pmid: 12750168
references.citation: Blood. 1998 Jul 1;92(1):76-82
references.pmid: 9639502
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Ann Oncol. 2003 Dec;14(12):1768-75
references.pmid: 14630683
references.citation: Leuk Lymphoma. 2002 Apr;43(4):805-11
references.pmid: 12153168
references.citation: Ann Oncol. 2009 Dec;20(12):1977-84
references.pmid: 19570965
references.citation: Ann Oncol. 2004 Oct;15(10):1467-75
references.pmid: 15367405
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Blood. 1997 Nov 1;90(9):3727-34
references.pmid: 9345059
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2740-6
references.pmid: 12860953
references.citation: J Clin Oncol. 2000 Jan;18(1):54-63
references.pmid: 10623693
references.citation: Ann Oncol. 1999 Sep;10(9):1079-86
references.pmid: 10572606
references.citation: Bone Marrow Transplant. 2001 Apr;27(7):711-6
references.pmid: 11360110
references.citation: Leuk Lymphoma. 1996 Dec;24(1-2):121-9
references.pmid: 9049968
references.citation: Haematologica. 2006 Mar;91(3):427-8
references.pmid: 16503553
references.citation: J Clin Oncol. 2000 Aug;18(16):3025-30
references.pmid: 10944137
references.citation: N Engl J Med. 1993 Apr 8;328(14):1002-6
references.pmid: 7680764
references.citation: Ann Oncol. 1997;8 Suppl 1:71-5
references.pmid: 9187435
references.citation: Blood. 2000 Dec 1;96(12):3712-8
references.pmid: 11090051
references.citation: J Clin Oncol. 2006 Jan 1;24(1):181-9
references.pmid: 16382127
references.citation: Acta Oncol. 2003;42(7):779-83
references.pmid: 14690165
references.citation: Eur J Cancer. 2002 Jan;38(1):75-81
references.pmid: 11750843
references.citation: Hematol J. 2004;5(4):304-11
references.pmid: 15297846
references.citation: Acta Oncol. 1993;32(1):69-72
references.pmid: 8466767
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120